Point72 Asset Management
ZNTL icon

Point72 Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Point72 Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-94,854
Closed -$222K – 4667
2026
Q1 		$222K Sell
94,854
-5,436
-5% -$14K ﹤0.01% 3480
2025
Q4 		$135K Buy
+100,290
New +$146K ﹤0.01% 3704

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Point72 Asset Management's ZNTL Position: Q2 2026 in Review

Point72 Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 94,854 shares — an estimated $222K sold.

Point72 Asset Management first reported a position in ZNTL in Q4 2025 and held it in 2 quarters. The position peaked at $222K in Q1 2026. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Point72 Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 94,854 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $222K.
  • Point72 Asset Management first reported a position in Zentalis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Point72 Asset Management's Zentalis Pharmaceuticals position peaked at $222K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.